The Experts below are selected from a list of 7149 Experts worldwide ranked by ideXlab platform
Cecilia S Robat - One of the best experts on this subject based on the ideXlab platform.
-
the use publication and future directions of immunocytochemistry in veterinary medicine a consensus of the Oncology Pathology working group
Veterinary and Comparative Oncology, 2017Co-Authors: H L Priest, K R Hume, David Killick, A Kozicki, V L Rizzo, Davis M Seelig, L A Snyder, Nora L Springer, Z M Wright, Cecilia S RobatAbstract:One of the primary objectives of the Oncology Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects of and provide guidelines for oncologic Pathology. Consensus is established through review of relevant peer-reviewed literature relative to a subgroup's particular focus. In this document, the authors provide descriptions of the literature reviewed, the review process, and a summary of the information gathered on immunocytochemistry. The intent of this publication is to help educate practitioners and pathologists on the process of immunocytochemistry and to provide a guide for the use of this technique in veterinary medicine. This document represents the opinions of the working group and the authors and does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.
-
The use, publication and future directions of immunocytochemistry in veterinary medicine: a consensus of the Oncology‐Pathology Working Group
Veterinary and comparative oncology, 2016Co-Authors: H L Priest, K R Hume, David Killick, A Kozicki, V L Rizzo, Davis M Seelig, L A Snyder, Nora L Springer, Z M Wright, Cecilia S RobatAbstract:One of the primary objectives of the Oncology Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects of and provide guidelines for oncologic Pathology. Consensus is established through review of relevant peer-reviewed literature relative to a subgroup's particular focus. In this document, the authors provide descriptions of the literature reviewed, the review process, and a summary of the information gathered on immunocytochemistry. The intent of this publication is to help educate practitioners and pathologists on the process of immunocytochemistry and to provide a guide for the use of this technique in veterinary medicine. This document represents the opinions of the working group and the authors and does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.
Bertrand Joseph - One of the best experts on this subject based on the ideXlab platform.
-
Caspase-8 inhibition represses initial human monocyte activation in septic shock model.
Oncotarget, 2016Co-Authors: Maria Jose Oliva-martin, Johanna Rodhe, Alejandro Carrillo-jimenez, Antonio J. Herrera, Albert Garcia-quintanilla, Teresa Caballero-velázquez, José A. Pérez-simón, Panagiotis Vlachos, Luis Ignacio Sánchez-abarca, Bertrand JosephAbstract:// Maria Jose Oliva-Martin 1,2,3 , Luis Ignacio Sanchez-Abarca 3 , Johanna Rodhe 2 , Alejandro Carrillo-Jimenez 1 , Pinelopi Vlachos 2 , Antonio Jose Herrera 1 , Albert Garcia-Quintanilla 1 , Teresa Caballero-Velazquez 3 , Jose Antonio Perez-Simon 3,* Bertrand Joseph 2,* and Jose Luis Venero 1,* 1 Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Universidad de Sevilla, Sevilla, Spain 2 Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden 3 Instituto de Biomedicina de Sevilla (IBiS)-/CSIC/ Universidad de Sevilla, Sevilla, Spain * Co-senior authors Correspondence: Maria Jose Oliva-Martin, email: // Keywords : sepsis, monocyte, inflammation, caspase-8, necroptosis, Pathology Section Received : January 16, 2016 Accepted : May 17, 2016 Published : May 26, 2016 Abstract In septic patients, the onset of septic shock occurs due to the over-activation of monocytes. We tested the therapeutic potential of directly targeting innate immune cell activation to limit the cytokine storm and downstream phases. We initially investigated whether caspase-8 could be an appropriate target given it has recently been shown to be involved in microglial activation. We found that LPS caused a mild increase in caspase-8 activity and that the caspase-8 inhibitor IETD-fmk partially decreased monocyte activation. Furthermore, caspase-8 inhibition induced necroptotic cell death of activated monocytes. Despite inducing necroptosis, caspase-8 inhibition reduced LPS-induced expression and release of IL-1β and IL-10. Thus, blocking monocyte activation has positive effects on both the pro and anti-inflammatory phases of septic shock. We also found that in primary mouse monocytes, caspase-8 inhibition did not reduce LPS-induced activation or induce necroptosis. On the other hand, broad caspase inhibitors, which have already been shown to improve survival in mouse models of sepsis, achieved both. Thus, given that monocyte activation can be regulated in humans via the inhibition of a single caspase, we propose that the therapeutic use of caspase-8 inhibitors could represent a more selective alternative that blocks both phases of septic shock at the source.
-
TAp73β-mediated suppression of cell migration requires p57Kip2 control of actin cytoskeleton dynamics.
Oncotarget, 2013Co-Authors: Johanna Rodhe, Edel Kavanagh, Bertrand JosephAbstract:// Johanna Rodhe 1 , Edel Kavanagh 1 and Bertrand Joseph 1 1 Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet, 171 76 Stockholm, Sweden. Correspondence: Bertrand Joseph, email: // Keywords : p73α, p73β, p57Kip2, actin cytoskeleton, cell migration, invasion. Received : January 23, 2013 Accepted : February 26, 2013 Published : February 27, 2013 Abstract The TP73 gene, a member of the p53 family, due to the use of different promoters and alternative splicing, is transcribed into different isoforms with contrasting attributes and which contribute to its functional diversity. Considerable efforts are made to identify the functional diversity of the p73 splicing variants during tumorigenesis.TAp73α and TAp73β isoforms have been shown to differentially regulate cell cycle progression, differentiation and apoptosis. Interestingly, a particular increase in expression of the TAp73 isoform, in favor of the α splicing variant, has been reported in multiple tumour types. Here, we report a distinctive role for TAp73β isoform in the control of cell migration and invasion. In fact, TAp73β-dependent induction of p57 Kip2 expression accounted for inhibitory effects on the actin cytoskeleton dynamics and thereby cancer cell motility. In contrast, TAp73α is not able to induce p57 Kip2 expression, and exhibits a positive effect on actin cytoskeleton dynamics as well as cell migration and invasion. In conclusion, the inhibitory effect on cell migration and invasion of TAp73β would qualify this distinct p73 isoform as tumor suppressor gene. In contrast, the promoting effect of TAp73α on cell motility and invasion strengthens the potential oncogenic activities of this p73 isoform .
-
TAp73alpha protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death.
Oncotarget, 2011Co-Authors: Naveen Reddy Muppani, Ulrika Nyman, Bertrand JosephAbstract:Naveen Muppani 1 , Ulrika Nyman 1,2 , and Bertrand Joseph 1 1 Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet, 171 76 Stockholm, Sweden 2 Present address: Ludwig Institute for Cancer Research, 171 77 Stockholm, Sweden Received: December 19, 2011; Accepted: December 21, 2011; Published: December 22, 2011; Keywords: p73, caspase-2, apoptosis, cancer Correspondence: Ulrika Nyman, email: // // Abstract Caspase-2 is ubiquitously expressed and the most evolutionarily conserved mammalian caspase. It can be activated by a range of death stimuli prior to Bax activation and the occurrence of apoptotic mitochondrial dysfunctions. Caspase-2 has also been reported to exert tumour suppressor function in vivo . The full length TAp73alpha isoform is found up-regulated in various tumour types, and is reported in a cell-type specific manner to repress drug-induced apoptosis. Here, we report that TAp73alpha represses caspase-2 enzymatic activity and by this means reduce caspase-2 induced Bax activation, loss of mitochondrial transmembrane potential and resulting apoptosis. The inhibitory effect on caspase-2 requires the presence of the DNA binding domain and SAM domain region of TAp73alpha. In conclusion, the ability of TAp73alpha to act as an inhibitor of caspase-2-induced cell death together with its up-regulation in certain tumour types strengthen the potential oncogenic activities for this protein.
H L Priest - One of the best experts on this subject based on the ideXlab platform.
-
the use publication and future directions of immunocytochemistry in veterinary medicine a consensus of the Oncology Pathology working group
Veterinary and Comparative Oncology, 2017Co-Authors: H L Priest, K R Hume, David Killick, A Kozicki, V L Rizzo, Davis M Seelig, L A Snyder, Nora L Springer, Z M Wright, Cecilia S RobatAbstract:One of the primary objectives of the Oncology Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects of and provide guidelines for oncologic Pathology. Consensus is established through review of relevant peer-reviewed literature relative to a subgroup's particular focus. In this document, the authors provide descriptions of the literature reviewed, the review process, and a summary of the information gathered on immunocytochemistry. The intent of this publication is to help educate practitioners and pathologists on the process of immunocytochemistry and to provide a guide for the use of this technique in veterinary medicine. This document represents the opinions of the working group and the authors and does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.
-
The use, publication and future directions of immunocytochemistry in veterinary medicine: a consensus of the Oncology‐Pathology Working Group
Veterinary and comparative oncology, 2016Co-Authors: H L Priest, K R Hume, David Killick, A Kozicki, V L Rizzo, Davis M Seelig, L A Snyder, Nora L Springer, Z M Wright, Cecilia S RobatAbstract:One of the primary objectives of the Oncology Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects of and provide guidelines for oncologic Pathology. Consensus is established through review of relevant peer-reviewed literature relative to a subgroup's particular focus. In this document, the authors provide descriptions of the literature reviewed, the review process, and a summary of the information gathered on immunocytochemistry. The intent of this publication is to help educate practitioners and pathologists on the process of immunocytochemistry and to provide a guide for the use of this technique in veterinary medicine. This document represents the opinions of the working group and the authors and does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.
Julius M. Liptak - One of the best experts on this subject based on the ideXlab platform.
-
prognostic and predictive significance of kit protein expression and c kit gene mutation in canine cutaneous mast cell tumours a consensus of the Oncology Pathology working group
Veterinary and Comparative Oncology, 2019Co-Authors: Douglas H. Thamm, Anne C. Avery, Davide Berlato, Craig A. Clifford, Joanne L Intile, Pamela D Jones, Debra A. Kamstock, Julie Bulmanfleming, Elizabeth A Hershey, Julius M. LiptakAbstract:One of the primary objectives of the Oncology-Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects of and provide guidelines for oncologic Pathology. Consensus is established through critical review of peer-reviewed literature relevant to a subgroup's particular focus. Subsequent acceptance and approval of the document by the OPWG membership at large establishes consensus. The intent of this publication is to help educate practitioners and pathologists on the value of diagnostics related to the KIT receptor tyrosine kinase for canine cutaneous mast cell tumours and to provide a guide for the use of these tests in veterinary medicine. This document represents the opinions of the OPWG and the authors and does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.
-
Prognostic and predictive significance of KIT protein expression and c‐kit gene mutation in canine cutaneous mast cell tumours: A consensus of the Oncology‐Pathology Working Group
Veterinary and comparative oncology, 2019Co-Authors: Douglas H. Thamm, Anne C. Avery, Davide Berlato, Julie Bulman-fleming, Craig A. Clifford, A. Elizabeth Hershey, Joanne L Intile, Pamela D Jones, Debra A. Kamstock, Julius M. LiptakAbstract:One of the primary objectives of the Oncology-Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects of and provide guidelines for oncologic Pathology. Consensus is established through critical review of peer-reviewed literature relevant to a subgroup's particular focus. Subsequent acceptance and approval of the document by the OPWG membership at large establishes consensus. The intent of this publication is to help educate practitioners and pathologists on the value of diagnostics related to the KIT receptor tyrosine kinase for canine cutaneous mast cell tumours and to provide a guide for the use of these tests in veterinary medicine. This document represents the opinions of the OPWG and the authors and does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.
Solange Peters - One of the best experts on this subject based on the ideXlab platform.
-
Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: Oncology, Pathology and health economic perspectives.
Expert review of anticancer therapy, 2013Co-Authors: James A. Lee, Lukas Bubendorf, Rolf A. Stahel, Solange PetersAbstract:Crizotinib is a first-in-class oral anaplastic lymphoma kinase (ALK) inhibitor targeting ALK-rearranged non-small-cell lung cancer. The therapy was approved by the US FDA in August 2011 and received conditional marketing approval by the European Commission in October 2012 for advanced non-small-cell lung cancer. A break-apart FISH-based assay was jointly approved with crizotinib by the FDA. This assay and an immunohistochemistry assay that uses a D5F3 rabbit monoclonal primary antibody were also approved for marketing in Europe in October 2012. While ALK rearrangement has relatively low prevalence, a clinical benefit is exhibited in more than 85% of patients with median progression-free survival of 8-10 months. In this article, the authors summarize the therapy and alternative test strategies for identifying patients who are likely to respond to therapy, including key issues for effective and efficient testing. The key economic considerations regarding the joint companion diagnostic and therapy are also presented. Given the observed clinical benefit and relatively high cost of crizotinib therapy, companion diagnostics should be evaluated relative to response to therapy versus correlation alone whenever possible, and both high inter-rater reliability and external quality assessment programs are warranted.
